Related Experiment Video
Updated: Jun 5, 2026

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
Clinical Need for Point-of-Care Testing for Diabetes in Clinical and Laboratory Improvement Amendments-Waived
Pamela R Kushner1, Vivian Fonseca2, James H Nichols3
1University of California, Irvine, Irvine, CA.
Abstract:
Point-of-care testing (POCT) has been used in multiple care settings for acute disease and, to a lesser extent, chronic disease testing. All POCT is regulated under the Clinical and Laboratory Improvement Amendments of 1988 (CLIA). CLIA-waived POCT requires no proficiency testing and can be carried out by nonlaboratory personnel. This review describes the benefits and limitations of POCT for cardiometabolic diseases and related conditions. It also explores the current U.S. regulatory environment for CLIA-waived POCT, highlighting the need for increased access.
Related Concept Videos
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Hypoglycemia and Glucagon
Type I Diabetes III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Hypoglycemia
Hyperglycemia

